Skip to content
MarketScale
‹ Back to IndustriesSciences

On the Look-Out for Dry Eyes

Tears play a critical role in maintaining eye health beyond emotional expression, serving to lubricate and nourish the eye. Dry eye syndrome occurs when tear production or quality is insufficient, leading to discomfort and potential vision complications. Early detection and treatment are important for managing dry eye conditions effectively.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Featured ·
Share
On the Look-Out for Dry Eyes

Key takeaways

01

Tears are essential for eye lubrication, nourishment, and overall eye health — not just emotional responses.

02

Dry eye syndrome is a common condition caused by insufficient tear production or poor tear quality.

03

Regular eye check-ups and early intervention can help identify and manage dry eye symptoms before they worsen.

For most of us, tears are associated solely with crying. In a moment of sadness or joy, we might shed a few tears–but otherwise, the curious water in our eyes is not something we typically worry about. Tears, as it turns out, are essential to maintaining eye health, helping to lubricate and nourish the eye with every blink. Insufficient tearing, however, can result in dry eye, a chronic issue that is becoming increasingly prevalent.

While it is particularly common in older adults, dry eye affects anyone whose body either does not produce enough tears, or simply produces poor quality tears. This may seem like a minor annoyance, but dry eye can lead to some serious complications. For instance, the tears you produce help clear away dirt or harmful particles from your eyes, and without this cleansing process, eye infections gain a foothold. Even barring infection, a lack of tears can lead to abrasion on the surface of the cornea, vision problems and even corneal ulcers

The rise in popularity of LASIK surgery has brought the condition of dry eye into prevalence. For the best surgical outcome, it is important to be able to detect and control dry eye prior to the procedure. Luckily, there are several tests to help detect this condition.

The Schirmer Test is perhaps the most straight forward as it involves placing a very thin strip of paper under the lower eyelid in order to measure tear production. In what is known as the “tear breakup time” (TBUT) test, a small amount of dye is placed in the eye to monitor tear distribution. For those concerned about tests that directly interact with the eye’s surface, a keratometer can be used to analyze the tear film through imaging. And rounding out our list of the more common tests for dry eye is MMP-9 Testing, which involves taking a small sample of tears from the bottom lid. It is quick and painless, providing results in minutes as to whether a patient is ready for LASIK or if further treatment is needed.

Luckily, dry eye is very treatable. It all comes down to managing the quantity of tears produced or drained from the eyes. If too few tears are produced, over-the-counter artificial tear solutions are available, or your doctor may prescribe higher strength eye drops if a larger increase in tear production is necessary. If, however, tears are being drained too quickly through the tear ducts, silicone plugs can be used to block the ducts so that moisture is kept in the eye longer. Finally, dietary supplements such as flaxseed oil or Omega-3 fatty acids are also helpful in treating this condition.

While dry eye certainly is more common in those over the age of 65, it is something everyone should be aware of, as it is often caused by allergic reactions or even a medication you may be taking for an entirely different condition.

About the author

F
Featured

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

F
Featured

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512